Hubei Honch Pharmaceutical is an API manufacturer based in China. It holds 11 active US drug master files across a filed portfolio of 10 molecules. Its GMP standing is certified by US FDA. Its most recent recorded inspection, by US FDA, closed on 20 March 2025 as VAI.
NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.
| Site | FDA FEI |
|---|---|
| China, China | 3009478588 |
| Molecule | Regulators | Docs |
|---|---|---|
| Vinblastine | US FDA | 2 |
| Bleomycin | US FDA | 1 |
| Bortezomib | US FDA | 1 |
| Fidaxomicin | US FDA | 1 |
| Melphalan | US FDA | 1 |
| Midostaurin | US FDA | 1 |
| Mitomycin | US FDA | 1 |
| Staurosporine | US FDA | 1 |
| Vincristine | US FDA | 1 |
| Vinorelbine | US FDA | 1 |
Also appears on these molecule pages
| Regulator | Filings | GMP certificates |
|---|---|---|
| US FDA | None | 1 |
Choose your molecules and target markets. Hubei Honch Pharmaceutical comes back tiered against every other supplier able to file there.
Start for free